Onco Wiki / Régime

Induction gemcitabine-cisplatine (GC) + chimioradiation concomitante de cisplatin (IMRT) - carcinome nasopharyngé avancé localement

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.

Source YAML: dossier complet

Notes

STUB — draft entity pending Clinical Co-Lead sign-off (CHARTER §6.1; dev-mode-exempted). Modern standard for locoregionally advanced NPC: induction gemcitabine-cisplatin (GC) x3 cycles before concurrent chemoradiation improved recurrence-free/overall survival vs concurrent CRT alone in higher-risk (Stage III-IVA) disease (Zhang et al., NEJM 2019 — GC-induction trial; exact effect-size figures pending verification against primary source). Concurrent cisplatin + RT backbone traces to Intergroup-0099 / Al-Sarraf (JCO 1998), which first established chemoradiation superior to RT alone in NPC; Intergroup-0099 also included an adjuvant cisplatin+5-FU tail that is DELIBERATELY OMITTED here — current practice (and the GC-induction trial design) favors induction-then-CCRT without a post-CRT adjuvant phase, consistent with the disease narrative supplied for this authoring pass. RT dose/fractionation intentionally NOT modeled as a formal RadiationCourse entity in this pass (out of scope per file- naming-convention guidance given); free-text approximate figures only.

Utilisé par

Indication

• IND-NPC-1L-LOCALLY-ADVANCED-CCRT - IND-NPC-1L-LOCALLY-ADVANCED-CCRT

Sources

• SRC-INTERGROUP-0099-ALSARRAF-1998 - Supérieurité de la chimioradiothérapie versus radiothérapie chez les patients avec na...